Orphan Drug Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Orphan Drug stocks.

Orphan Drug Stocks Recent News

Date Stock Title
May 3 FOLD ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
May 3 RGEN Repligen First Quarter 2024 Earnings: EPS Misses Expectations
May 2 RGEN Repligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call Transcript
May 2 RGEN Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
May 2 RGEN Repligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...
May 1 RGEN Repligen Corporation (RGEN) Q1 2024 Earnings Call Transcript
May 1 CYTK Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
May 1 FOLD Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
May 1 IONS 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
May 1 RGEN Repligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst Projections
May 1 RGEN Repligen (RGEN) Misses Q1 Earnings Estimates
May 1 RGEN Repligen reports mixed Q1 results; reaffirms FY24 outlook
May 1 RGEN Repligen Reports First Quarter 2024 Financial Results
May 1 FOLD Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
Apr 30 RGEN Repligen Q1 2024 Earnings Preview
Apr 30 IONS Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Apr 29 CYTK Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Apr 29 BIVI BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment
Apr 29 BIVI BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Orphan Drug

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.In the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.

Browse All Tags